Naftzger J. Christopher
- SEC CIK
- 0001496194
No open-market purchases or sales filed in the past year.
Current role at each company
- ABUS Arbutus Biopharma CorpGeneral Counsel and CCOas of Feb 19, 2025
- Nabriva Therapeutics plcGeneral Counsel and Corp Secas of Aug 15, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Naftzger J. Christopher as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ABUS Arbutus Biopharma Corp
General Counsel and CCO1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | Naftzger J. ChristopherGeneral Counsel and CCO | SSale | −11.3K | $3.28 | −$37.2K | −11.6%86.2K after | 10b5-1 |
Nabriva Therapeutics plc
General Counsel and Corp Sec1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 28, 2021 (view filing) | Dec 27 | 1 day | Naftzger J. ChristopherGeneral Counsel and Corp Sec | PPurchase | +7.00K | $0.59 | +$4.13K | New position7.00K after |